Ticker: OGN

Sun Pharma is acquiring US-based Organon in an $11.75 billion all-cash transaction, marking the largest overseas deal in India's pharmaceutical sector and expanding its specialty medicine footprint globally.

Organon & Co. (NYSE: OGN) has reported its financial results for the second quarter ended June 30, 2025, revealing both positive and negative trends in its income statement. Key Highlights: Revenues: Declined slightly to $1.594 billion in Q2 2025 from $1.607 billion in Q2 2024. Gross Profit: Dro...

Organon & Co. (NYSE: OGN) - Q1 2025 Financial Overview As of the end of Q1 2025, Organon reported a notable decline in several key financial metrics, signaling both challenges and opportunities within the company. Here are the pertinent details from the latest income statement: Positive Aspects: ...